Friday, August 26, 2022 Daily Archives

How Our Partnerships Move Your Life-Changing Biologics to Market: Two Case Studies

by

Muctarr Sesay, chief scientific officer, Goodwin Biotechnology. Goodwin Biotechnology’s mission is to minimize manufacturing risks associated with complex biopharmaceuticals, including antibody–drug conjugates (ADCs), bioconjugated vaccines, and multispecific antibodies. Sesay described his company’s capabilities, which span from preclinical process development through commercial supply. Currently, the Goodwin site in Fort Lauderdale, FL, is equipped for 200-L and 500-L bioreactors in both stainless-steel and single-use formats. The company can perform drug substance and drug product manufacturing as well as fill–finish steps, all according…

August 26, 2022

Novartis waves goodbye to biosimilars with Sandoz split

by

Novartis will spin-off its generics division Sandoz, which includes a portfolio of eight biosimilar products. In 2018, Novartis granted its generic and biosimilar medicine division Sandoz more autonomy while claiming to be “completely committed” to the business. Since then, analysts and investors have been hedging their bets as to when the inevitable spin-off would therefore occur. Following a strategic review last year, the Swiss firm has now cemented a separation plan to be completed by the second half of 2023.…

August 26, 2022

ABEC injects $11m in NC single-use plant

by

The expansion will see ABEC invest $11 million to add 50,000 square feet at its facility located in Wilson, North Carolina. According to ABEC, a bioprocess vendor, the expansion will increase its single-use disposable container (DC) manufacturing capacity within its CSR biomanufacturing solutions business. “CSR (custom single run) is ABEC’s single-use equipment product line used for manufacturing vaccines and pharmaceuticals based on biotechnology. The product line includes single-use bioreactors, fermenters, solutions prep and hold systems, and filtration systems,” a spokesperson…

August 26, 2022